Abstract
Approximately 5% of all primary brain tumors are oli-godendroglial tumors. Their incidence is in the range of 0.5 per 100,000 per year. The median age at diagnosis is 40–45 (www.cbtrus.org).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bent van den MJ, Chinot O, Boogerd W et al (2003a) Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14:599–602
Bent van den MJ, Taphoorn MJ, Brandes AA et al (2003b) Phase II study of fi rst-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971. J Clin Oncol 21:2525–2528
Bent van den MJ, Kros JM, Heimans JJ et al (1998) Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy. Neurology 51:1140–1145
Bent van den MJ, Afra D, de Witte O et al, for the EORTC Radiotherapy and Brain Tumor Groups and the UK Medical Research Council. (2005) Long-term effi cacy of early versus delayed radiotherapy for low-grade astrocytoma and oligo-dendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990
Bent van den MJ, Carpentier AF, Brandes AA et al (2006) Adjuvant procarbazine, lomustine, and vincristine improve progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocy-tomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol 24:2715–2722
Brandes AA, Tosini A, Cavallo G et al (2006) Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendro-glioma: a prospective GICNO study. J Clin Oncol 29:4746–4753
Buckner JC, Gesme D Jr, O'Fallon JR et al (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: effi cacy and associations with chromosomal abnormalities. J Clin Oncol 21:251–255
Cairncross JG, Macdonald D, Ludwin S et al, for the National Cancer Institute of Canada Clinical Trials Group (1994) Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12:2013–2021
Cairncross G, Berkey B, Shaw E et al (2006) Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendro-glioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol 24:2707–2714
Louis DN, Ohgaki H, Wiestler OD et al (2007) WHO Classification of Tumours of the Central Nervous System. IARC Press, Lyon, France
Macdonald DR, Cascino TL, Schold SC et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280
Möllemann M, Wolter M, Felsberg J et al (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385
Pignatti F, Bent van den MJ, Curran D et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–2084
Quinn JA, Reardon DA, Friedman AH et al (2003) Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21:646–651
Vredenburgh JJ, Desjardins A, Herndon 2nd JE et al (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259
Weller M, Berger H, Hartmann C et al, for the German Glioma Network (2007) Combined 1p/19q loss in oligoden-droglial tumors: predictive or prognostic biomarker? Clin Cancer Res 13:6933–6937
Wick W, Weller M, for the Neurooncology Working Group of the German Cancer Society (2008) NOA-04 randomized phase III study of sequential radiochemotherapy of anaplas-tic glioma with PCV or temozolomide. J Clin Oncol 2008, ASCO Proceedings, #LBA2007
Zlatescu MC, Tehrani Yazdi AR, Sasaki H et al (2001) Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms. Cancer Res 61:6713–6715
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hofer, S., Happold, C., Weller, M. (2010). Oligodendroglioma. In: Tonn, JC., Westphal, M., Rutka, J.T. (eds) Oncology of CNS Tumors. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-02874-8_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-02874-8_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-02873-1
Online ISBN: 978-3-642-02874-8
eBook Packages: MedicineMedicine (R0)